-
公开(公告)号：EP3585371B1
公开(公告)日：2024-07-10
申请号：EP18757194.8
申请日：2018-02-14
IPC分类号： A61K31/155 , A61K31/165 , A61K31/17 , A61K31/519 , A61K45/06 , A61P9/12 , A61P7/10
CPC分类号： A61K45/06 , A61K31/519 , A61P7/10 , A61P9/12
-
公开(公告)号：EP3031907B1
公开(公告)日：2021-01-06
申请号：EP16153526.5
申请日：2009-11-06
IPC分类号： C12N5/0789 , C07C405/00 , A61K31/00 , A61K38/19 , A61K31/395 , A61K31/4035 , A61K31/405 , A61K31/4196 , A61K31/5415 , C12N9/02 , C12N15/63 , A61P3/00 , A61P7/00 , A61P7/06 , A61P29/00 , A61P35/02 , A61P43/00 , A61K35/12 , A61K35/28 , A61K35/50 , A61K35/51
-
公开(公告)号：EP2875049B1
公开(公告)日：2018-12-26
申请号：EP13737614.1
申请日：2013-07-18
申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) , Assistance Publique - Hôpitaux de Paris , Indiana University Research and Technology Corporation
IPC分类号： C07K16/18 , C12N15/113 , C12N15/115 , A61P13/12
CPC分类号： C12N15/113 , C07K16/18 , C07K2317/76 , C12N15/1138 , C12N15/115 , C12N2310/11 , C12N2310/16 , C12N2310/315
摘要： The present invention relates to methods for preventing and treating chronic kidney disease (CKD).
-
4.发明授权
公开(公告)号：EP2872493B1
公开(公告)日：2018-11-14
申请号：EP13817021.2
申请日：2013-07-12
申请人： Indiana University Research and Technology Corporation , The Brigham and Women's Hospital, Inc. , The University of Massachusetts
IPC分类号： C07D261/06 , C07D413/12 , A61K31/42 , A61P21/00
CPC分类号： C07D493/04 , C07C311/37 , C07C2601/08 , C07C2603/20 , C07D213/75 , C07D215/227 , C07D215/44 , C07D221/10 , C07D231/14 , C07D233/88 , C07D239/47 , C07D239/82 , C07D261/06 , C07D261/14 , C07D261/18 , C07D263/48 , C07D267/14 , C07D277/46 , C07D285/135 , C07D401/04 , C07D405/04 , C07D405/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04 , C07D487/04 , C07K14/47
摘要： Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene.
-
公开(公告)号：EP2825162B1
公开(公告)日：2018-09-12
申请号：EP13761860.9
申请日：2013-03-13
IPC分类号： A61K31/122 , A61K45/06 , A61K31/16 , A61K31/164 , A61K31/201 , A61K31/381 , A61K31/45 , A61K31/475 , A61K31/495 , A61K31/519 , A61K31/5375 , A61K31/573 , A61K31/704 , A61P35/02
CPC分类号： C07D295/192 , A61K31/16 , A61K31/164 , A61K31/201 , A61K31/381 , A61K31/45 , A61K31/475 , A61K31/495 , A61K31/519 , A61K31/5375 , A61K31/573 , A61K31/704 , A61K45/06 , C07C49/563 , C07C59/90 , C07C235/78 , C07D211/40 , A61K2300/00
摘要： Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (ALL) in its various forms.
-
6.发明授权GIGAXONIN FUSION PROTEIN AND METHODS FOR TREATING GIANT AXONAL NEUROPATHY 有权GIGAXON融合蛋白和治疗巨大轴突神经病变的方法
公开(公告)号：EP2771367B1
公开(公告)日：2017-12-06
申请号：EP12843112.9
申请日：2012-10-25
CPC分类号： C07K14/47 , A61K38/00 , C07K2319/10
摘要： The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.
-
公开(公告)号：EP2563781B1
公开(公告)日：2016-10-26
申请号：EP11775554.6
申请日：2011-04-28
发明人： MCCARTHY, James, R.
IPC分类号： C07D263/20 , C07D295/135 , C07D303/36
CPC分类号： C07D263/20
-
公开(公告)号：EP2986314A2
公开(公告)日：2016-02-24
申请号：EP14768322.1
申请日：2014-03-14
发明人： DIMARCHI, Richard D. , KOU, Binbin
IPC分类号： A61K38/26
CPC分类号： A61K47/48338 , A61K38/22 , A61K38/26 , A61K45/06 , A61K47/542 , C07K14/605 , A61K2300/00
摘要： Peptide-based prodrugs having significantly extended half lives are disclosed herein.
摘要翻译： 与亲本肽或多肽相比，提供生物活性肽（或多肽）的前药衍生物，其在血清中表现出延长的半衰期和体内延长的作用。 在一些实施方案中，肽选自胰高血糖素，毒蜥外泌肽-4，GLP-1，GLP-2，GIP，血管活性肠肽（VIP），垂体腺苷酸环化酶活化多肽27（PACAP-27），肽 组氨酸甲硫氨酸（PHM），胃泌酸调节素，促胰液素，骨钙素，生长激素释放激素，以及类似物，衍生物和缀合物。
-
公开(公告)号：EP2976083A2
公开(公告)日：2016-01-27
申请号：EP14767362.8
申请日：2014-03-20
IPC分类号： A61K31/505
CPC分类号： G01N33/56983 , A61K49/0017 , C09B11/08 , C09B11/24 , C09B23/02 , C09B57/00 , C09B57/02 , C09B57/10 , C12Q1/18 , G01N2333/02 , G01N2500/02 , G01N2500/04 , G01N2500/10
摘要： Heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery are described. The present invention relates to heteroaryldihydropyrimidine (HAP)-based fluorescent stains (compounds), as well as uses of such stains as diagnostic reagents, viral-tracking agents, and/or tools for drug discovery.
摘要翻译： 描述了基于杂芳基二氢嘧啶（HAP）的荧光染料（化合物），以及这种染色剂作为诊断试剂，病毒跟踪剂和/或用于药物发现的工具的用途。
-
10.发明公开O-GLYCOSYLATED CARBOXY TERMINAL PORTION (CTP) PEPTIDE-BASED INSULIN AND INSULIN ANALOGUES 有权基于带有CARBOXYTERMINIERTER零件和胰岛素类似物肽O-糖基化胰岛素
公开(公告)号：EP2925345A1
公开(公告)日：2015-10-07
申请号：EP13861070.4
申请日：2013-11-22
IPC分类号： A61K38/28
摘要： Compositions and formulations comprising insulin or insulin analogs comprising a carboxy terminal portion (CTP) peptide comprising amino acids 112-118 to 145 of the beta subunit of human chorionic gonadotropin (hCGβ) or a partial variant thereof that includes at least one O-glycosylation site of the CTP peptide, wherein the CTP peptide of the CTP peptide-based insulin or insulin analog is O-glycosylated are described. In particular embodiments, the O-glycosylated insulin analogs are produced in vivo and in further embodiments, the O-glycosylated CTP-based insulin analogs comprise predominantly mannotriose and mannotetrose O-glycans or predominantly mannose O-glycans.
-
-
-
-
-
-
-
-
-
搜索结果
240 条记录 (耗时 0.052 秒)
